Pcsa stock.

What is the target price for Processa Pharma (PCSA) stock? A. The latest price target for Processa Pharma ( NASDAQ: PCSA) was reported by HC Wainwright & Co. on Monday, May 13, 2024. The analyst ...

Pcsa stock. Things To Know About Pcsa stock.

Price Performance Review of PCSA. On Tuesday, Processa Pharmaceuticals Inc [NASDAQ:PCSA] saw its stock jump 3.81% to $2.18. Over the last five days, the stock has gained 36.25%. Processa Pharmaceuticals Inc shares have fallen nearly -67.42% since the year began. Nevertheless, the stocks have fallen -82.70% over the past one year.©2024 Processa Pharmaceuticals, Inc. All Rights Reserved. Privacy Policy Disclaimer Sitemap Manage Cookie Preferences. Market Data copyright © 2024 QuoteMedia.Processa Pharma (NASDAQ: PCSA) just reported results for the first quarter of 2024. Processa Pharma reported earnings per share of -$1.11. The company did not report any revenue for the quarter ...PCSA Stock Price. -82.28% May 2024 Mar 2024 Jan 2024 Nov 2023 Sep 2023 Jul 2023 0 5 10 15 20. 52 Week Range. 1.40 18.00. Day Range. 2.08 2.19. EPS (FWD) -3.82. PE. - Div Rate. - Yield. - Market...PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer therapeutic. The company has also gotten the regulatory green light to move into a Phase 2 trial for its breast cancer treatment.

Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304. The reverse stock split is intended for the Company to regain compliance with the minimum bid price requirement of $1.00 per share of common stock …

Processa Pharmaceuticals to Present at the MedInvest Biotech and Pharma Investor Conference. HANOVER, MD, March 28, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of …HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) ( Processa or the Company ), a clinical-stage pharmaceutical company focused on developing the next... Insider Buying: Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) Director Buys 8,000 Shares of Stock Zolmax • 3 months ago.

Track Processa Pharmaceuticals Inc (PCSA) Stock Price, Quote, latest community messages, chart, news and other stock related information. Share your ideas and get valuable insights from the community of like minded traders and investorsPCS3117 for Pancreatic Cancer. On June 17, 2021, we entered into a licensing agreement with Ocuphire Pharma, Inc. (NASDAQ: OCUP) to license in RX-3117. RX-3117 is an oral, anticancer agent with an improved pharmacological profile relative to gemcitabine and other nucleoside analogs. Rx-3117 has a family of patents extending into 2036 as well as ...Processa Pharmaceuticals Inc (PCSA) stock is down -0.85% while the S&P 500 has risen 0.4% as of 12:34 PM on Wednesday, Feb 14. PCSA has fallen -$0.02 from the previous closing price of $2.34 on volume of 37,450 shares. Over the past year the S&P 500 has risen 20.23% while PCSA has fallen -85.85%. PCSA lost -$22.82 per share the over …3 days ago · T-Mobile US, Inc. specializes in mobile telecommunication services. Sales break down by activity as follows: - mobile telecommunication services (80.5%): mobile telephone service, long-distance telephone service, data transmission, Internet access, directory services, etc. serving 119.7 million subscribers at the end of 2023; - equipment sales (18%): primarily handsets and accessories; - other ...

Potential Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shareholders may wish to note that the Co-Founder, Patrick Lin, recently bought US$125k worth of stock, paying US$4.00 for each share.While ...

Jan 26, 2024 ... (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage ... shares of common stock (or pre-funded warrants in lieu thereof) and ...

May 6, 2024 · Rhea-AI Summary. Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) has closed a public offering of 1,555,555 shares of common stock and common warrants, raising $7.0 million in gross proceeds. The offering price per share was $4.50, with the common warrants having an exercise price of $4.50 per share and a term of five years. PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ... Processa Pharmaceuticals Inc. is a development-stage pharmaceutical company that uses a unique approach to develop not discover drugs that help in the treatment of oncology and other high unmet medical need diseases with unparalleled regulatory science and clinical expertise. Our drug candidates are intended for patients who have limited ... 2 in Stock, despatched same dayAdditional quantity lead time 9 days. Product Details. This holder is ideal for supporting and clamping printed circuit boards ... View today's Processa Pharmaceuticals Inc stock price and latest PCSA news and analysis. Create real-time notifications to follow any changes in the live stock price.

Find More Stocks. Use our equities screener to discover other potential opportunities. Find Similar Stocks Find Stocks Similar to PCSAYou may have a lot of questions if you are interested in investing in the stock market for the first time. One question that beginning investors often ask is whether they need a br...Free PCSA Stock Alerts. $2.09. -0.04 (-1.88%) (As of 05/10/2024 ET) Compare. Share. Today's Range. $2.08. . $2.19. 50-Day Range. $1.52. . $2.99. 52-Week …The Company’s common stock will begin trading on a reverse stock split-adjusted basis at the opening of the market on Monday, January 22, 2024. Following the reverse stock split, the Company’s common stock will continue to trade on the Nasdaq Capital Market under the symbol “PCSA” with the new CUSIP number 74275C304.Processa Pharmaceuticals, Inc. (US:PCSA) has 13 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 112,706 shares.Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) announces Dr. David Young, President of Research and Development, will present at the MedInvest Oncology Investor Conference. Processa CEO George Ng will be available for one-on-one meetings with investors at the conference venue. ... N/A Ranked by Stock Gains. N/A Ranked by …At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life.

PCSA. 2.090. -1.88%. Webull offers Processa Pharmaceuticals Inc (PCSA) historical stock prices, in-depth market analysis, NASDAQ: PCSA real-time stock quote data, in-depth charts. PCSA / Processa Pharmaceuticals, Inc. off-exchange short sale volume is shown in the following chart. Short Sale volume shows the number of trades marked as short sales in various trading venues. For more information on how to interpret this data, read this information notice provided by FINRA. Update Frequency: Daily at Close of Day

The consensus among . 1 Wall Street analyst covering (NASDAQ: PCSA) stock is to Buy PCSA stock.Out of . 1 analyst, 0 (0%) are recommending PCSA as a Strong Buy, 1 (100%) are recommending PCSA as a Buy, 0 (0%) are recommending PCSA as a Hold, 0 (0%) are recommending PCSA as a Sell, and 0 (0%) are recommending PCSA as a Strong Sell.If …Get Processa Pharmaceuticals Inc (PCSA.OQ) real-time stock quotes, news, price and financial information from Reuters to inform your trading and investmentsOct 7, 2020 · Potential Processa Pharmaceuticals, Inc. (NASDAQ:PCSA) shareholders may wish to note that the Co-Founder, Patrick Lin, recently bought US$125k worth of stock, paying US$4.00 for each share.While ... Processa Pharma (NASDAQ: PCSA) just reported results for the first quarter of 2024. Processa Pharma reported earnings per share of -$1.11. The company did not … Complete Processa Pharmaceuticals Inc. stock information by Barron's. View real-time PCSA stock price and news, along with industry-best analysis. Price vs Fair Value. View History. PCSA is trading within a range we consider fairly valued. Price. $2.06. May 10, 2024. Fair Value. $3.41. May 10, 2024.

N/A. Q2 2024 EPS Estimate Trends. Current. -$0.90. 1 Month Ago. N/A. 3 Months Ago. N/A. Processa Pharmaceuticals Inc. analyst estimates, including PCSA earnings per share estimates and analyst ...

Sprint Nextel Merger - August 12, 2005. On August 12, 2005, the merger between Sprint Corporation (NYSE: FON) and Nextel Communications Inc. (NASDAQ: NXTL) was completed and Sprint Corporation changed its name to Sprint Nextel Corporation. Sprint Nextel common stock began trading on the New York Stock Exchange Monday, August 15, 2005, under the ...

Discover historical prices for PCSA stock on Yahoo Finance. View daily, weekly or monthly format back to when Processa Pharmaceuticals, Inc. stock was issued. PCSA technical analysis. This gauge displays a real-time technical analysis overview for your selected timeframe. The summary of Processa Pharmaceuticals, Inc. is based on the most popular technical indicators, such as Moving Averages, Oscillators and Pivots. Learn more. This info isn't a recommendation for what you should personally do, so ...Open 2.1100. Bid 2.0500 x 100. Ask 2.1100 x 200. Day's Range 2.0813 - 2.1900. 52 Week Range 1.4000 - 18.0000. Volume 56,712. Avg. Volume 1,484,388. Market Cap (intraday) 5.973M. Beta (5Y Monthly)...The three major U.S. stock exchanges are the New York Stock Exchange (NYSE), the NASDAQ and the American Stock Exchange (AMEX). As of 2014, the NYSE is the largest and most prestig...Processa Pharmaceuticals Inc. is a development-stage pharmaceutical company that uses a unique approach to develop not discover drugs that help in the treatment of oncology and other high unmet medical need diseases with unparalleled regulatory science and clinical expertise. Our drug candidates are intended for patients who have limited ...... PCSA Market Cap against competitors ... stock's last observed trading price. In the case of ... Stock ScreenerStock IdeasMetrics ExplorerChart EditorWatchlists ... Discover historical prices for PCSA stock on Yahoo Finance. View daily, weekly or monthly format back to when Processa Pharmaceuticals, Inc. stock was issued. Company. Processa Pharmaceuticals, Inc. 7380 Coca Cola Drive. Suite 106. Hanover, MD 21076. T: 443.776.3133. F: 443.288.4420‬. The mission of Processa is to develop products with existing clinical evidence of efficacy for patients with unmet or underserved medical conditions who need treatment options that improve survival and/or quality of life.Find the latest Processa Pharmaceuticals, Inc. (PCSA) stock discussion in Yahoo Finance's forum. Share your opinion and gain insight from other stock traders and investors.Interactive Chart for Processa Pharmaceuticals, Inc. (PCSA), analyze all the data with a huge range of indicators.Stock control is important because it prevents retailers from running out of products, according to the Houston Chronicle. Stock control also helps retailers keep track of goods th...

Dec 13, 2023 · Processa Pharmaceuticals ( NASDAQ: PCSA) lost ~16% on Wednesday after the drug developer disclosed feedback it received from the FDA regarding a mid-stage trial for its chemotherapy candidate ... PCSA has fallen -$0.02 from the previous closing price of $2.34 on volume of 37,450 shares. Over the past year the S&P 500 has risen 20.23% while PCSA has fallen -85.85%. PCSA lost -$22.82 per share the over the last 12 months. Click Here to get the full Stock Report for Processa Pharmaceuticals Inc stock. At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, social interaction and mortgage rates that help you manage your financial life. Stock Analysis provides real-time and historical data, news, charts and analysis for PCSA, a clinical-stage pharmaceutical company focused on developing the next generation of 5 …Instagram:https://instagram. cop detectoryuma sun newspapertoast online orderingua airline check in PCSA stock is up about 90% as of this writing, although shares climbed more than 150% at one point today. Undergirding sentiment are encouraging safety results regarding Processa’s anti-cancer ...Short interest is the volume of Processa Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of March 31st, investors have sold 35,800 shares of PCSA short. 1.56% of Processa Pharmaceuticals' shares are currently sold short. Learn More on Processa Pharmaceuticals' current short interest. flight to greenville scwatch sparkle 2012 HANOVER, Md., April 11, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs with improved efficacy and safety, presented two abstracts at the American Association for Cancer … pixel 8 pro screen protector Processa Pharmaceuticals Inc stock price live, this page displays NASDAQ PCSA stock exchange data. View the PCSA premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Processa Pharmaceuticals Inc real time stock price chart below.T-Mobile US, Inc. specializes in mobile telecommunication services. Sales break down by activity as follows: - mobile telecommunication services (80.5%): mobile telephone service, long-distance telephone service, data transmission, Internet access, directory services, etc. serving 119.7 million subscribers at the end of 2023; - equipment sales (18%): primarily handsets and accessories; - other ...Price vs Fair Value. View History. PCSA is trading within a range we consider fairly valued. Price. $2.06. May 10, 2024. Fair Value. $3.41. May 10, 2024.